infl
uenza
virus
caus
respiratori
tract
infect
patient
underli
lung
diseas
chronic
obstruct
pulmonari
diseas
copd
associ
exacerb
excess
morbid
mortal
typic
infl
uenza
b
associ
rel
mild
local
outbreak
wherea
infl
uenza
caus
worldwid
pandem
upon
infect
two
antigen
present
viral
surfac
hemagglutinin
neuraminidas
result
human
immun
sinc
mani
subtyp
antigen
exist
vari
time
immun
popul
blunt
vaccin
advoc
highrisk
group
includ
patient
underli
lung
diseas
elderli
need
repeat
annual
vaccin
expect
cover
expect
chang
viral
antigen
start
earli
antivir
drug
especi
neuraminidaseinhibitor
prescrib
adjunct
nonspecifi
c
intervent
attempt
shorten
diseas
durat
prevent
complic
case
infl
uenza
infect
current
effect
antivir
drug
specifi
calli
patient
copd
proven
believ
risk
pandem
outbreak
infl
uenza
grow
three
pandem
occur
centuri
recent
result
million
death
worldwid
new
outbreak
may
similar
devast
result
like
affect
elderli
peopl
patient
reduc
immun
patient
suffer
chronic
diseas
chronic
obstruct
pulmonari
diseas
copd
chronic
obstruct
pulmonari
diseas
character
larg
irrevers
progress
airfl
ow
limit
airfl
ow
obstruct
associ
infl
ammatori
process
bronchial
mucosa
patient
current
exsmok
mani
patient
one
exacerb
per
year
associ
acceler
declin
lung
function
decreas
qualiti
life
nhlbi
exacerb
respons
half
direct
diseaserel
cost
care
viral
infect
includ
infl
uenza
respiratori
syncyti
viru
rsv
mani
virus
import
caus
exacerb
excess
morbid
mortal
copd
wedzicha
wilkinson
et
al
season
outbreak
viral
infect
patient
copd
risk
respiratori
illnessrel
hospit
irrespect
age
diseas
sever
gors
et
al
prevent
earli
treatment
exacerb
therefor
believ
import
target
manag
copd
inhal
steroid
may
reduc
number
sever
exacerb
patient
sever
airfl
ow
obstruct
frequent
exacerb
effect
limit
burg
et
al
jone
inhal
bronchodil
may
similar
effect
annual
infl
uenza
vaccin
recommend
copd
guidelin
neuraminidas
inhibitor
avail
treatment
infl
uenza
evid
role
infl
uenza
virus
pathogenesi
copd
caus
exacerb
discuss
review
current
recommend
prevent
treatment
infl
uenza
patient
copd
summar
infl
uenza
viru
belong
orthomyxoviru
group
infl
uenza
viru
spheric
fi
lament
envelop
viru
viru
strain
character
differ
hemagglutinin
h
neuraminidas
n
subclass
hemagglutinin
surfac
glycopeptid
aid
attach
viru
specifi
c
receptor
site
wall
suscept
host
cell
facilit
entri
virus
cell
enzym
neuraminidas
facilit
cell
penetr
pinocytosi
stimul
releas
virus
host
cell
bud
cell
membran
matrosovich
et
al
viru
exist
two
main
form
b
infl
uenza
gener
respons
epidem
pandem
infl
uenza
b
caus
milder
gener
local
less
sever
outbreak
eg
school
camp
lesser
known
c
form
rare
caus
diseas
human
h
subtyp
nine
n
subtyp
identifi
ed
infl
uenza
virus
new
antigen
variant
infl
uenza
develop
irregular
interv
process
antigen
shift
wherea
point
mutat
infl
uenza
b
virus
result
chang
amino
acid
h
n
glycoprotein
respons
humor
immun
result
antigen
drift
zambon
chang
render
individu
immun
respons
less
abl
combat
new
variant
result
major
shift
antigen
profi
le
virus
caus
epidem
immun
system
less
blunt
minor
antigen
drift
caus
less
sever
outbreak
stamboulian
et
al
appear
infl
uenza
type
associ
million
death
worldwid
pandem
occur
result
emerg
hong
kong
infl
uenza
minor
antigen
drift
sinc
caus
smaller
outbreak
variou
area
world
avian
fl
u
caus
emerg
reemerg
repres
major
chang
viral
surfac
antigen
transmiss
human
shown
seriou
threat
beigel
et
al
infl
uenza
thought
occur
approxim
world
popul
annual
case
infl
uenza
acut
febril
respiratori
diseas
occur
annual
outbreak
vari
sever
incub
period
infl
uenza
day
infl
uenza
typic
caus
extens
destruct
airway
epitheli
cell
symptom
start
abruptli
consist
fever
shiver
diffus
pain
extrem
mani
patient
present
earli
promin
system
symptom
headach
sore
throat
dri
cough
persist
sever
week
monto
et
al
mortal
high
elderli
especi
patient
chronic
respiratori
cardiac
diseas
recoveri
take
month
secondari
bacteri
infect
common
particularli
streptococcu
pneumonia
haemophilu
infl
uenza
staphylococcu
aureu
superinfect
caus
pneumonia
mortal
brundag
otherwis
healthi
individu
treatment
consist
paracetamol
bed
rest
suffi
cient
oral
intak
fl
uid
wiselka
patient
copd
patient
heart
kidney
diseas
earli
treatment
appropri
antibiot
recommend
nathan
et
al
suscept
person
usual
smoker
exposur
inhal
noxiou
particl
gase
result
infl
ammat
bronchial
mucosa
lung
parenchyma
pulmonari
vasculatur
nhlbi
process
believ
import
imbal
proteinas
antiproteinas
oxid
stress
mani
cell
mediat
involv
pathogenesi
infl
ammat
copd
time
infl
ammat
result
structur
chang
bronchial
wall
destruct
lung
parenchyma
emphysema
consequ
irrevers
airfl
ow
obstruct
ga
exchang
abnorm
host
factor
believ
import
pathogenesi
characterist
infl
ammat
copd
virus
proud
chungwai
also
host
behavior
respons
virus
possibl
aberr
antivir
host
respons
may
infl
uenc
persist
infl
ammat
follow
exposur
virus
stabl
copd
latent
respiratori
virus
rsv
adenovirus
associ
acceler
lung
function
declin
independ
smoke
statu
exacerb
frequenc
lower
airway
bacteri
load
mallia
johnston
rsv
may
also
associ
system
infl
ammat
whether
virus
differ
infl
uenza
strain
similar
effect
stabl
copd
present
unknown
shown
respiratori
virus
rsv
also
infl
uenza
virus
enter
bronchial
epitheli
cell
replic
result
epitheli
cell
destruct
necrosi
result
increas
permeabl
mucosa
allow
pathogen
irrit
penetr
lead
neurogen
infl
ammat
substanc
p
bradykinin
dysfunct
contribut
bronchial
hyperrespons
wilkinson
et
al
airway
hyperrespons
caus
excess
airway
narrow
copd
patient
virus
involv
infl
ammat
stabl
copd
also
trigger
exacerb
rohd
et
al
wedzicha
exacerb
commonli
defi
ned
event
natur
cours
diseas
character
chang
patient
baselin
dyspnea
cough
andor
sputum
beyond
normal
daytoday
variat
acut
onset
may
warrant
chang
regular
medic
patient
underli
copd
nhlbi
respiratori
virus
consid
amongst
import
trigger
exacerb
copd
exacerb
found
associ
symptomat
cold
precipit
virus
seemung
et
al
wedzicha
rhinoviru
enterovirus
belong
picornaviru
group
rna
virus
stand
coronaviru
adenoviru
rsv
infl
uenza
b
parainfl
uenza
virus
link
copd
exacerb
often
multipl
virus
detect
rohd
et
al
variou
mechan
believ
involv
way
virus
induc
aggrav
exacerb
rhinovirus
attach
airway
epithelium
cell
intercellular
adhes
therebi
caus
infl
ammatori
cell
recruit
activ
also
viral
infect
found
associ
increas
oxid
stress
activ
nuclear
factor
express
stressrespons
gene
wedzicha
proport
exacerb
relat
isol
infl
uenza
viru
differ
studi
probabl
infl
uenc
number
copd
patient
receiv
infl
uenza
vaccin
gors
et
al
infl
uenza
infect
caus
excess
morbid
mortal
copd
may
affect
progress
diseas
older
studi
popul
receiv
infl
uenza
vaccin
hospit
rate
acut
exacerb
copd
substanti
higher
infl
uenza
season
noninfl
uenza
season
simonsen
et
al
consid
infl
uenc
differ
respiratori
virus
stabl
copd
import
role
viral
infect
exacerb
vaccin
potenti
effect
way
reduc
morbid
mortal
caus
exacerb
unfortun
signifi
cant
variat
within
major
viru
type
caus
diseas
limit
success
vaccin
programm
sinc
infl
uenza
virus
display
antigen
shift
drift
new
vaccin
must
develop
regular
interv
respons
arriv
new
pandem
strain
new
vaccin
must
made
avail
suffi
cient
quantiti
effect
vaccin
usual
inactiv
viru
vaccin
contain
viru
strain
type
type
b
depend
similar
strain
vaccin
viru
strain
like
circul
upcom
winter
protect
occur
circul
antibodi
h
n
stimul
cytotox
tcell
respons
protect
infl
uenza
vaccin
effect
patient
last
one
year
new
vaccin
must
prepar
year
cover
expect
chang
antigen
consequ
defi
nition
suppli
limit
case
emerg
epidem
obvious
benefi
vaccin
largest
epidem
year
vaccin
strain
similar
epidem
strain
current
standard
guidelin
therefor
recommend
annual
infl
uenza
vaccin
patient
copd
costeffect
intervent
spite
fact
random
studi
infl
uenza
vaccin
patient
copd
nhlbi
evid
support
recommend
larg
stem
observ
studi
elderli
subject
larg
cohort
studi
nearli
elderli
patient
vaccin
result
reduct
number
hospit
respiratori
condit
reduct
allcaus
mortal
compar
nonvaccin
subject
nichol
et
al
subject
chronic
lung
diseas
vaccin
result
reduct
hospit
decreas
death
rate
infl
uenza
season
nichol
et
al
metaanalysi
publish
effect
infl
uenza
vaccin
gross
colleagu
show
reduct
respiratori
ill
reduct
hospit
reduct
caus
death
reduct
pneumonia
vaccin
subject
random
clinic
trial
wongsurakiat
colleagu
demonstr
infl
uenza
vaccin
highli
effect
prevent
acut
respiratori
ill
relat
infl
uenza
viru
infect
regardless
sever
copd
comorbid
diseas
age
gender
smoke
statu
extens
review
literatur
limit
number
studi
specifi
calli
perform
copd
patient
publish
format
cochran
review
pool
colleagu
conclud
administr
inactiv
infl
uenza
vaccin
clinic
import
signifi
cant
effect
reduc
exacerb
caus
infl
uenza
occur
three
week
vaccin
probabl
effect
total
number
exacerb
copd
patient
epidem
year
proport
exacerb
caus
infl
uenza
higher
effect
like
greater
limit
data
effect
infl
uenza
vaccin
number
durat
hospit
mortal
outcom
term
lung
function
report
also
conclud
evid
increas
earli
exacerb
pool
et
al
yet
experi
mani
clinician
transient
increas
symptom
may
occur
week
vaccin
chronic
obstruct
pulmonari
diseas
patient
suscept
unfavor
outcom
case
infl
uenza
infect
vaccin
help
prevent
exacerb
pneumonia
hospit
patient
effect
limit
certain
extent
less
ideal
immun
rate
antigen
shift
decreas
effect
vaccin
exacerb
occur
result
infl
uenza
viru
infect
treat
inhal
bronchodil
system
corticosteroid
antibiot
aim
suspect
bacteri
superinfect
lowflow
oxygen
appropri
nonspecifi
c
measur
suffi
cient
fl
uid
intak
bedrest
antipyret
drug
andor
cool
mist
humidifi
er
recommend
otherwis
healthi
adult
four
drug
current
avail
prophylaxi
treatment
influenza
infect
amantadin
amantadin
rimantadin
ninhibitor
zanamivir
oseltamivir
amantadin
inhibit
viral
uncoat
insid
host
cell
effect
influenza
effect
limit
emerg
resist
strain
also
sever
toxic
sideeffect
reduc
use
jefferson
et
al
ninhibitor
effect
nsubtyp
therefor
amantadin
use
strain
influenza
act
prevent
releas
virion
infect
host
cell
gener
recommend
use
ninhibitor
routin
season
influenza
use
drug
associ
publichealth
measur
pandem
situat
moscona
furthermor
drug
signific
effect
asymptomat
influenza
neuraminidaseinhibitor
test
variou
scenario
studi
specifi
calli
perform
copd
patient
current
avail
publish
prophylaxi
treatment
trial
suggest
zanamivir
oseltamivir
effect
prevent
treat
symptom
complic
infl
uenza
infect
prevent
infect
prevent
voidanc
virus
nose
literatur
regard
effect
ninhibitor
prevent
treat
infl
uenza
healthi
adult
recent
review
jefferson
colleagu
excel
review
summar
result
random
control
trial
test
ninhibitor
control
clinic
prophylaxi
postexposur
prophylaxi
treatment
trial
conclud
oseltamivir
daili
oral
dose
mg
inhal
zanamivir
mg
daili
effect
prophylaxi
infl
uenzalik
ill
compar
placebo
whether
higher
dose
effect
uncertain
effi
caci
oseltamivir
compar
placebo
oral
administ
dose
mg
daili
symptomat
infl
uenza
dose
mg
daili
effi
caci
jefferson
et
al
author
argu
use
drug
routin
season
infl
uenza
control
gener
ninhibitor
low
effect
high
effi
caci
appear
welltoler
possibl
emerg
resist
put
forward
oseltamivir
resist
report
around
zambon
hayden
monto
et
al
household
transmiss
season
infl
uenza
shown
interrupt
welliv
et
al
neuraminidas
inhibitor
recommend
treatment
atrisk
patient
present
infl
uenzalik
ill
start
within
hour
onset
symptom
ideal
treatment
start
earlier
prefer
within
hour
onset
symptom
aoki
et
al
current
control
studi
effect
safeti
ninhibitor
specifi
calli
copd
patient
patient
underli
respiratori
diseas
avail
observ
studi
conclud
ninhibitor
use
addit
infl
uenza
vaccin
patient
disord
respiratori
system
includ
copd
highrisk
develop
infl
uenza
relat
complic
gors
et
al
williamson
pegram
condit
affect
respiratori
complic
pneumonia
bronchiti
present
robust
data
avail
support
use
ninhibitor
avian
infl
uenza
jefferson
et
al
oseltamivir
use
uncontrol
set
data
infl
uenza
copd
regard
effect
allow
reach
fi
rm
conclus
leneva
et
al
unlik
older
antivir
drug
amantadin
rimantadin
ninhibitor
rare
caus
central
nervou
system
advers
effect
yet
drug
may
sideeffect
zanamivir
shown
caus
bronchospasm
suscept
patient
use
caution
copdpati
freund
et
al
patient
prescrib
zanamivir
fastact
bronchodil
avail
side
effect
zanamivir
includ
diarrhea
wherea
oseltamivir
shown
abl
caus
nausea
vomit
retch
nicholson
et
al
infl
uenza
virus
shown
involv
pathophysiolog
copd
stabl
diseas
exacerb
annual
infl
uenza
vaccin
recommend
patient
proven
effect
case
vaccin
remain
gold
standard
prevent
infl
uenza
atrisk
subject
includ
patient
chronic
diseas
copd
recommend
treatment
infl
uenza
copd
patient
includ
regular
nonspecifi
c
measur
gener
believ
help
patient
use
earli
prefer
within
hour
onset
symptom
ninhibitor
zanamivir
oseltamivir
use
adjunct
vaccin
manag
patient
risk
develop
infl
uenza
relat
complic
copd
patient
ninhibitor
use
routin
season
infl
uenza
control
even
patient
copd
seriou
epidem
pandem
use
recommend
conjunct
public
health
measur
copd
patient
other
alik
